Gilead readies to file Sovaldi in Japan
This article was originally published in Scrip
Executive Summary
Gilead Sciences has reported positive topline data from its Japanese Phase III trial of sofosbuvir (Sovaldi) in combination with ribavirin for the treatment of genotype 2 chronic hepatitis C virus (HCV) infection.